<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068597</url>
  </required_header>
  <id_info>
    <org_study_id>CCS1477-02</org_study_id>
    <nct_id>NCT04068597</nct_id>
  </id_info>
  <brief_title>Study to Evaluate CCS1477 in Haematological Malignancies</brief_title>
  <official_title>An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy in Patients With Advanced Haematological Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellCentric Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellCentric Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477
      in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk
      Myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The RP2D/MTD dose will be determined in Parts A and B. Parts C-E will run in parallel after the completion of Parts A and B.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Treatment-related adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Laboratory abnormalities characterised by type, frequency, severity and timing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as number of patients who have a response according to
RECIL criteria (NHL)
IMWG criteria (Multiple myeloma)
ELN recommendations 2017 (AML)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the time from start of treatment until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CCS1477</measure>
    <time_frame>35 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CCS1477</measure>
    <time_frame>35 days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of CCS1477</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Haematological Malignancy</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CCS1477 dose escalation NHL/MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 dose escalation AML/High risk MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 expansion phase NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 expansion phase MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS1477 expansion phase AML/High risk MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCS1477</intervention_name>
    <description>Oral</description>
    <arm_group_label>CCS1477 dose escalation AML/High risk MDS</arm_group_label>
    <arm_group_label>CCS1477 dose escalation NHL/MM</arm_group_label>
    <arm_group_label>CCS1477 expansion phase AML/High risk MDS</arm_group_label>
    <arm_group_label>CCS1477 expansion phase MM</arm_group_label>
    <arm_group_label>CCS1477 expansion phase NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of consent

          -  ECOG performance status 0-2

          -  Patients with confirmed (per standard disease specific diagnostic criteria), relapsed
             or refractory haematological malignancies (NHL, MM and AML)

          -  Must have previously received standard therapy

          -  Adequate organ function

        Exclusion Criteria:

          -  Intervention with any chemotherapy, investigational agents or other anti-cancer drugs
             within 14 days or 5 half-lives of the first dose

          -  Major surgical procedure or significant traumatic injury within 4 weeks of the first
             dose of study treatment

          -  Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken
             within 2 weeks of the first dose of study treatment

          -  Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment

          -  Patients should discontinue statins prior to starting study treatment

          -  CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first
             dose of study treatment

          -  Any unresolved reversible toxicities from prior therapy &gt;CTCAE grade 1 at the time of
             starting study treatment (except alopecia and grade 2 neuropathy)

          -  Any evidence of severe or uncontrolled systemic diseases

          -  Any known uncontrolled inter-current illness

          -  QTcF prolongation (&gt; 480 msec)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Somervaille</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Clegg, PhD</last_name>
    <phone>+44 7464547447</phone>
    <email>Karen.Clegg@cellcentric.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomasz Knurowski, MD, MFPM</last_name>
    <phone>+44 1252 842255</phone>
    <email>Tomasz.Knurowski@cellcentric.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Knapper</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harriet Walter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Somervaille</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer and Haematology Centre</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Vyas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

